

Table 1. Frequency of the autoantibodies in COVID-19 patients and healthy controls

	COVID-19 patients				Controls (n=100)	OR (95% CI) of presence of antibody in patients of all severity compared with controls	P value
	Asymptomatic (n=21)	Mild and moderate (n=17)	Severe and critical (n=14)	Total (n=52)			
Antinuclear antibody, no. (%)	2 (9.5)	2 (11.8)	3 (21.4)	7 (13.5)	13 (13)	1.04 (0.4–2.8)	0.936
IgA rheumatoid factor, no. (%)	9 (42.9)	6 (35.3)	6 (42.9)	21 (40.4)	10 (10)	6.10 (2.6–14.4)	<0.001
IgM rheumatoid factor, no. (%)	0	2 (11.8)	1 (7.1)	3 (5.8)	15 (15)	0.35 (0.1–1.3)	0.095
IgG anticardiolipin antibody, no. (%)	8 (38.1)	6 (35.3)	4 (28.6)	18 (34.6)	0	108 (6.3–1837)	<0.001
IgA anticardiolipin antibody, no. (%)	10 (47.6)	8 (47.1)	8 (57.1)	26 (50)	9 (9)	10.1 (4.2–24.2)	<0.001
IgG anti- β 2-glycoprotein I, no. (%)	11 (52.4)	6 (35.3)	6 (42.9)	23 (44.2)	0	160 (9.4–2716)	<0.001
IgA anti- β 2-glycoprotein I, no. (%)	12 (57.1)	8 (47.1)	11 (78.6)	31 (59.6)	2 (2)	72.3 (16.0–326)	<0.001

CI: confidence interval; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M; OR: odds ratio
Chi-square test was carried out for each comparison